Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides

Clinica Chimica Acta

Volumn 443, Issue , 2015, Pages 17-24

  Clerico, Aldo ^a   Passino, Claudio ^a   Franzini, Maria ^a   Emdin, Michele ^a  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Cardiac endocrine function; Cardiovascular risk; Heart failure; Immunoassay methods; Natriuretic peptides; Troponins

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

BLOOD ANALYSIS; CARDIOVASCULAR RISK; CLINICAL LABORATORY; DIAGNOSTIC ACCURACY; DISEASE MARKER; FOLLOW UP; HEART FAILURE; HUMAN; IMMUNOASSAY; PATIENT ASSESSMENT; PEPTIDE ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; STANDARDIZATION; LABORATORY DIAGNOSIS;

BIOMARKERS; CLINICAL LABORATORY SERVICES; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES;

EID: 84924228354     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.003     Document Type: Review

References (128)

1. NICE (National Institute of Clinical Excellence) Clinical Guideline 5. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care July 2003, 1-44. [London].
2. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:1115-1140.
3. Nieminen M.S., Böhm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:384-416.
4. Hunt S.A., American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1-e82.
5. Adams K.F., Lindenfeld J., Arnold J.M.O., Baker D.W., Barnard D.H., Baughman K.L. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006, 12:10-38.
6. Braunwald E., Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 2000, 102(20 Suppl. 4):IV14-IV23.
7. Dipla K., Mattiello J.A., Jeevanandam V., Houser S.R., Margulies K.B. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998, 97:2316-2322.
8. Eichhorn E.J., Bristow M.R. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996, 94:2285-2296.
9. Vittorini S., Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. Clin Chem Lab Med 2008, 46:748-763.
10. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004, 25:1187-1196.
11. Macabasco-O'Connell A., Miller P.S. Biomarkers for heart failure. Prog Cardiovasc Nurs 2006, 21:215-218.
12. De Virginy D.R. Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart faille: a clinical review. Heart Fail Rev 2006, 11:333-334.
13. Vasan S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
14. Lainscak M., von Haehling S., Springer J., Anker S.D. Biomarkers for chronic heart failure. Heart Fail Monit 2007, 5:77-82.
15. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
16. Emdin M., Vittorini S., Passino C., Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail 2009, 11:331-335.
17. Maisel A.S., McCullough P.A. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 2003, 4(Suppl. 4):S3-S12.
18. Thygesen K., Mair J., Mueller C., et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012, 33:2001-2006.
19. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
20. Clerico A., Recchia F.A., Passino C., Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17-H29.
21. Clerico A., Giannoni A., Vittorini S., Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011, 301:H12-H20.
22. Clerico A., Fontana M., Ripoli A., Emdin M. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv Clin Chem 2009, 48:163-179.
23. Troughton R., Michael Felker G., Januzzi J.L. Natriuretic peptide-guided heart failure management. Eur Heart J 2014, 35:16-24.
24. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
25. Porapakkham P., Porapakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010, 170:507-514.
26. Troughton R.W., Frampton C.M., Brunner-La Rocca H.P., et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014, 35:1559-1567.
27. Januzzi J.L., Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013, 127:500-507.
28. Clerico A., Giannoni A., Prontera T., Giovannini S. High-sensitivity troponin: a new toll for pathophysiological investigation and clinical practice. Adv Clin Chem 2009, 49:1-30.
29. Apple F.S., Collinson P.O. Analytical characteristics of high-sensitivity cardiac troponin assay. Clin Chem 2012, 58:54-61.
30. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003, 108:833-838.
31. Sato Y., Yamada T., Taniguchi R., et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001, 103:369-374.
32. Setsuta K., Seino Y., Takahashi N., et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999, 84:608-611. [A9].
33. Hudson M.P., O'Connor C.M., Gattis W.A., et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 2004, 147:546-552.
34. Fonarow G.C., Peacock W.F., Horwich T.B., et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 2008, 101:231-237.
35. Peacock W.F.I.V., De Marco T., Fonarow G.C., et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008, 358:2117-2126.
36. Ilva T., Lassus J., Siirila-Waris K., et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail 2008, 10:772-779.
37. Missov E., Calzolari C., Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997, 96:2953-2958.
38. Ather S., Hira R.S., Shenoy M., et al. Recurrent low-level troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. Int J Cardiol 2011, 301:H2351-H2361.
39. Januzzi J.L., Filippatos G., Nieminen M., et al. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: heart failure section. Eur Heart J 2012, 33:2265-2271.
40. Tang W.H., Shrestha K., Shao Z., et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011, 108:385-390.
41. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
42. Lok D.J., van der Meer P., de la Porte P.W., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
43. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
44. Felker G.M., Fiuzat M., Shaw L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012, 5:72-78.
45. Fermann G.J., Lindsell C.J., Storrow A.B., et al. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers 2012, 17:706-713.
46. Lopez-Andrès N., Rossignol P., Iraqi W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14:74-81.
47. Anand I.S., Rector T.S., Kuskowski M., et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013, 15:511-518.
48. Carrasco-Sánchez F.J., Aramburu-Bodas O., Salamanca-Bautista P., et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol 2013, 169:177-182.
49. Chen K., Jiang R.J., Wang C.Q., et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci 2013, 17:1005-1011.
50. de Boer R.A., Edelmann F., Cohen-Solal A., Mamas M.A., Maisel A., Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013, 15:1095-1101.
51. Lok D.J., Klip I.T., Lok S.I., et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 2013, 112:831-837.
52. Motiwala S.R., Szymonifka J., Belcher A., et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013, 15:1157-1163.
53. van der Velde A.R., Gullestad L., Ueland T., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013, 6:219-226.
54. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607-613.
55. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008, 54:752-756.
56. Rehman S.U., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008, 52:1458-1465.
57. Manzano-Fernandez S., Mueller T., Pascual-Figal D., et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011, 107:259-267.
58. Aldous S.J., Richards A.M., Troughton R., Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail 2012, 18:304-310.
59. Henry-Okafor Q., Collins S.P., Jenkins C.A., et al. Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes. Open Biomark J 2012, 2012:1-8.
60. Bayes-Genis A., Zamora E., de Antonio M., et al. Soluble ST2 serum concentration and renal function in heart failure. J Card Fail 2013, 19:768-775.
61. Breidthardt T., Balmelli C., Twerenbold R., et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 2013, 19:821-828.
62. Chen L.Q., de Lemos J.A., Das S.R., Ayers C.R., Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem 2013, 59:536-546.
63. Wang Y.C., Yu C.C., Chiu F.C., et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 2013, 19:163-168.
64. Gruson D., Lepoutre T., Ahn S.A., Rousseau M.F. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol 2014, 172:e250-e252.
65. Kattan M.W. Evaluating a new marker's predictive contribution. Clin Cancer Res 2004, 10:822-824.
66. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002, 105:310-315.
67. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
68. Hense H.W. Observations, predictions and decisions - assessing cardiovascular risk assessment. Int J Epidemiol 2004, 33:235-239.
69. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
70. Price P.C., Christensen R.H. Evidence-based laboratory medicine: principles, practice, and outcome 2007, 1-545. AACC Press, Washington DC. 2nd ed.
71. Marshall D.A., O'Brien B.J. Economic evaluation of diagnostic tests. Evidence-based laboratory medicine - from principles to outcomes 2003, 159-186. AACC Press, Washington DC. P.C. Price, R.H. Christensen (Eds.).
72. Wang T.J. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011, 123:551-565.
73. Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) [Accessed September 12, 2012]. http://clinicaltrials.gov/ct2/show/NCT01685840?term=GUIDE+IT&rank=1.
74. Clerico A. The increasing impact of laboratory medicine on clinical cardiology. Clin Chem Lab Med 2003, 41:871-883.
75. Clerico A., Zucchelli G.C., Pilo A., Passino C., Emdin M. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006, 44:366-378.
76. Clerico A., Fortunato A., Ripoli A., Prontera C., Zucchelli G.C., Emdin M. Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. Clin Chem Lab Med 2008, 46:804-808.
77. Cantinotti M., Storti S., Parri M.S., Prontera C., Murzi B., Clerico A. Reference intervals for brain natriuretic peptide in healthy newborns and infants measured with an automated immunoassay platform. Clin Chem Lab Med 2010, 48:697-700.
78. Giannoni A., Giovannini S., Clerico A. Measurement of circulating concentrations of cardiac troponin I and T in healthy subjects: a tool for monitoring myocardial tissue renewal?. Clin Chem Lab Med 2009, 47:1167-1177.
79. Luckenbill K.N., Christenson R.H., Jaffe A.S., et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008, 54:619-621.
80. Clerico A., Vittorini S., Passino C. Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clin Chem Lab Med 2011, 4:1949-1954.
81. Goetze J.P. Biosynthesis of cardiac natriuretic peptides. Results Probl Cell Differ 2010, 50:97-120.
82. Katrukha A.G., Bereznikova A.V., Filatov V.L., et al. Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem 1998, 44:2433-2440.
83. Panteghini M. Assay-related issues in the measurement of cardiac troponins. Clin Chim Acta 2009, 402:88-93.
84. Tate J.R., Bunk D.M., Christenson R.H., et al. Standardisation of cardiac troponin I measurement: past and present. Pathology 2010, 42:402-408.
85. Panteghini M., Pagani F., Yeo K.T., et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004, 50:327-332.
86. Clerico A., Del Ry S., Giannessi D. Measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000, 46:1529-1534.
87. Rawlins M.L., Owen W.E., Roberts W.L. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005, 123:439-445.
88. Apple F.S., Panteghini M., Ravkilde J., et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005, 51:486-493.
89. Apple F.S., Wu A.H., Jaffe A.S., et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure. Circulation 2007, 116:e95-e98.
90. Prontera C., Zaninotto M., Giovannini S., et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmoCheck study. Clin Chem Lab Med 2009, 47:762-768.
91. Clerico A., Zaninotto M., Prontera C., et al. State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study. Clin Chim Acta 2012, 414:112-119.
92. Wu A.H.B., Feng Y.J., Moore R., et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. Clin Chem 1998, 44:1198-1208.
93. Apple F.S. Standardization of cardiac troponin I assays will not occur in my lifetime. Clin Chem 2012, 58:169-171.
94. Christenson R.H., Duh S.H., Apple F.S., et al. Standardization of cardiac troponin I assays: round robin of ten candidate reference materials. Clin Chem 2001, 47:431-437.
95. Christenson R.H., Bunk D.M., Schimmel H., Tate J.R., IFCC Working Group on Standardization of Troponin I Point: put simply, standardization of cardiac troponin I is complicated. Clin Chem 2012, 58:165-168.
96. Gantzer M.L., Miller W.G. Harmonization of measurement procedures: how do we get it done?. Clin Biochem Rev 2012, 33:95-100.
97. Iervasi G., Clerico A. Harmonization of free thyroid hormone test: a mission impossible?. Clin Chem Lab Med 2011, 49:43-48.
98. Liang F., O'Rear J., Schellenberger U., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007, 49:1071-1078.
99. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004, 49:1503-1510.
100. Goetze J.P. ProBNP-derived peptides in cardiac disease. Scand J Clin Lab Invest 2004, 64:497-510.
101. Giuliani I., Rieunier F., Larue C., et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006, 52:1054-1061.
102. Seferian K.R., Tamm N.N., Semenov A.G., et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007, 53:866-873.
103. Hammerer-Lercher A., Halfinger B., Sarg B., et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008, 54:858-865.
104. Goetze J.P., Rehfeld J.F. Peptide hormones and their prohormones as biomarkers. Biomark Med 2009, 3:335-338.
105. Dries D.J., Ky B., Wu A., Rame J.E., Putt M., Cappola T. Simultaneous assessment of unprocessed ProBNP 1-108 in addition to processed BNP32 improves risk stratification in ambulatory patients with systolic heart failure. Circ Heart Fail 2010, 3:220-227.
106. Goetze J.P., Kastrup J., Rehfeld J.F. The paradox of increased natriuretic hormones in congestive heart failure patients: does the endocrine heart also fail in heart failure?. Eur Heart J 2003, 24:1471-1472.
107. Goetze J.P., Kastrup J., Pedersen F., Rehfeld J.F. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002, 48:1035-1042.
108. Macheret F., Boerrigter G., McKie P., et al. Pro-B-type natriuretic peptide 1-108 circulates in the general community: plasma determinants and detection of left ventricular systolic dysfunction. J Am Coll Cardiol 2011, 57:1386-1395.
109. Shimizu H., Masuta K., Aono K., et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002, 316:129-135.
110. Shimizu H., Masuta K., Asada H., Sugita K., Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003, 334:233-239.
111. Schellenberger U., O'Rear J., Guzzetta A., Jue R.A., Protter A.A., Pollitt N.S. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006, 451:160-166.
112. Seferian K.R., Tamm N.N., Semenov A.G., et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008, 54:866-873.
113. Crimmins D.L., Kao J.L. A glycosylated form of the human cardiac hormone pro B-type natriuretic peptide is an intrinsically unstructured monomeric protein. Arch Biochem Biophys 2008, 475:36-41.
114. Semenov A.G., Postnikov A.B., Tamm N.N., et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem 2009, 55:489-498.
115. Miller W.L., Phelps M.A., Wood C.M., et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011, 4:355-360.
116. Semenov A.G., Tamm N.N., Seferian K.R., et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010, 56:1166-1176.
117. Jiang J., Wu S., Wang W., et al. Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J Biol Chem 2011, 286:10066-10072.
118. Knappe S., Wu F., Masikat M.R., Wu Q. Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem 2003, 278:52363-52370.
119. Dong N., Chen S., Yang J., et al. Plasma soluble corin in patients with heart failure. Circ Heart Fail 2010, 3:207-211.
120. Semenov A.G., Seferian K.R., Tamm N.N., et al. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin Chem 2011, 57:883-890.
121. Emdin M., Passino C., Clerico A. Natriuretic peptide assays revisited: do we need pro-B-type natriuretic peptide?. J Am Coll Cardiol 2011, 57:1396-1398.
122. Del Ry S., Cabiati M., Clerico A. Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure. Pharmacol Res 2013, 76:190-198.
123. Clerico A., Prontera C., Emdin M., et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma BNP and NT-proBNP concentrations. Clin Chem 2005, 51:445-447.
124. Franzini M., Masotti S., Prontera C., et al. Systematic differences between BNP immunoassays: comparison of methods using standard protocols and quality control materials. Clin Chim Acta 2013, 424:287-291.
125. Niederkofler E.E., Kiernan U.A., O'Rear J., et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008, 1:258-264.
126. Hawkridge A.M., Heublein D.M., Bergen H.R., Cataliotti A., Burnett J.C., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005, 102:17442-17447.
127. Miller W.L., Grill D.E., Jaffe A.S. Comparison of novel pro-BNP1-108 and standard BNP assays in heart failure patients. Clin Chim Acta 2012, 413:920-926.
128. Emdin E., Clerico A., Clemenza F., et al. Consensus document. Recommendations for the clinical use of cardiac natriuretic peptides. J Cardiovasc Med (Ital Heart J) 2005, 6:430-446.